



March 6, 2017

## **Arbutus to Participate in Upcoming Investor Conferences**

VANCOUVER, British Columbia and DOYLESTOWN, Pa., March 06, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the company will be participating in two upcoming investor conferences.

- | Cowen 37<sup>th</sup> Annual Health Care Conference, March 6-8, 2017, Boston, MA
- | Barclays Global Healthcare Conference, March 14-16, 2017, Miami, FL

### **About Arbutus**

Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Arbutus is headquartered in Vancouver, BC, Canada with facilities in Doylestown, PA, USA. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

#### Contact Information

##### Investors

Adam Cutler

Senior Vice President, Corporate Affairs

Phone: 604.419.3200

Email: [acutler@arbutusbio.com](mailto:acutler@arbutusbio.com)

##### Media

Please direct all media inquiries to: [media@arbutusbio.com](mailto:media@arbutusbio.com)